Sign In
Buy NKTR
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026
SAN FRANCISCO, July 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026, after th
Does Nektar (NKTR) Have the Potential to Rally 104.06% as Wall Street Analysts Expect?
10:55am, Tuesday, 28'th Jul 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 104.1% in Nektar (NKTR). While the effectiveness of this highly sought-after metric is questionable, the positi
Nektar Therapeutics (NASDAQ:NKTR) Shares Gap Up – What’s Next?
02:02am, Sunday, 26'th Jul 2026
Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) shares gapped up before the market opened on Friday. The stock had previously closed at $69.36, but opened at $73.31. Nektar Therapeutics shares la
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 24'th Jul 2026
SAN FRANCISCO, July 24, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on July 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors grant
NKTR Up on Start of Phase III Program on Rezpeg for Atopic Dermatitis
10:56am, Wednesday, 22'nd Jul 2026
Nektar begins two phase III ZENITH AD studies of rezpeg for moderate-to-severe atopic dermatitis, with a third study set to start in September. Shares rise.
Two global registrational Phase 3 trials initiated in ZENITH AD program Phase 3 program based upon clinically meaningful efficacy and favorable safety data observed in 393-patient Phase 2b study with
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 26'th Jun 2026
SAN FRANCISCO, June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on June 19, 2026, the Organization and Compensation Committee of Nektar's Board of Directors grant
What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year
03:39pm, Wednesday, 24'th Jun 2026
Robin sold 20,000 shares over two days for a transaction value of $1.22 million at a weighted average price of $60.75 per share. This sale represented 26.64% of his direct common stock holdings and re
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
07:55am, Tuesday, 23'rd Jun 2026
Big pharma's appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology d
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Wednesday, 03'rd Jun 2026
SAN FRANCISCO, June 3, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on May 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors grant
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
06:15pm, Wednesday, 27'th May 2026
SAN FRANCISCO, May 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the 2026 Jefferies Global Healthcare Co
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares
10:09am, Saturday, 16'th May 2026
This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials.
Nektar Therapeutics Q1 Earnings Call Highlights
04:09pm, Friday, 08'th May 2026
Nektar Therapeutics NASDAQ: NKTR outlined plans to advance its lead regulatory T-cell (Treg) therapy rezpegaldesleukin (REZPEG) into late-stage development, while also reporting first-quarter 2026 fin
Nektar Q1 Earnings & Revenues Lag Estimates, Pipeline in Focus
01:56pm, Friday, 08'th May 2026
NKTR misses Q1 earnings and revenue estimates. Investor focus stays on rezpeg as the company advances late-stage studies in autoimmune diseases.
Nektar Therapeutics (NKTR) Q1 2026 Earnings Call Transcript
05:11am, Friday, 08'th May 2026
Nektar Therapeutics (NKTR) Q1 2026 Earnings Call Transcript
